Proteomics

Dataset Information

0

Impact of PD1/PD-L1 Inhibition on Bone Remodeling: a Prospective Clinical Study and ex-vivo Validation.


ABSTRACT: Background Skeletal morbidity in cancer patients has a major impact on quality of life and preserving bone health while improving outcomes is an important goal of modern antitumor treatment strategies. Despite their widespread use in early disease stages, the effects of immune-checkpoint inhibitors (ICI) on the skeleton are still poorly defined. Here, we initiated a comprehensive investigation of the impact of ICI on bone turnover by longitudinal assessment of bone turnover markers (BTM) in cancer patients and by validation in a novel bioengineered 3D model of bone remodeling. Methods Serum markers of bone resorption (C-terminal telopeptide, CTX) and formation (procollagen type I N-propeptide, PINP; and osteocalcin, OCN) were measured before each ICI application (PD1 inhibitors, PD1i or PD-L1 inhibitors, PD1i) for 6 months or until disease progression in patients with advanced cancer and no evidence of bone metastases. To validate the in vivo results, we evaluated osteoclast (OC) and osteoblast (OB) differentiation upon treatment with ICI. In addition, their effect on bone remodeling was assessed by immunohistochemistry, immunofluorescence and proteomics analysis in a dynamic 3D model of the bone multicellular unit (BMU). Results The longitudinal assessment of BTM revealed a significant decrease in CTX levels after 3 weeks, followed by a return to baseline levels within 3 months. In contrast, serum levels of PINP and OCN gradually increased from baseline to the last postbaseline assessment. In vitro, ICI impaired the maturation of preosteoclasts by inhibiting STAT3/NFATc1 signaling, but not JNK, ERK and AKT; while lacking any direct effect on osteogenesis. However, using our novel bioengineered 3D bone model, which enables the simultaneous differentiation of OB and OC precursor cells, we confirmed the uncoupling of the OC/OB activity upon ICI treatment by demonstrating impaired OC maturation along with increased OB differentiation. Conclusion Our study indicates that the inhibition of the PD1/PD-L1 signaling axis interferes with the OB/OC coupling of bone turnover and may potentially exert a protective effect on bone by impairing the differentiation OCs and indirectly promoting osteogenesis.

INSTRUMENT(S): Orbitrap Eclipse

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mesenchymal Stem Cell, Peripheral Blood Mononuclear Cell

SUBMITTER: Benjamin Neuditschko  

LAB HEAD: Franz Herzog

PROVIDER: PXD047604 | Pride | 2024-05-21

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
HD-PBMC_hMSC_BGS_report.tsv Tabular
HD-PBMC_hMSC_OC_OB_1.raw Raw
HD-PBMC_hMSC_OC_OB_2.raw Raw
HD-PBMC_hMSC_OC_OB_IgG_1.raw Raw
HD-PBMC_hMSC_OC_OB_IgG_2.raw Raw
Items per page:
1 - 5 of 20
altmetric image

Publications

Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.

Gassner Tamara T   Chittilappilly Christina C   Pirich Theo T   Neuditschko Benjamin B   Hackner Klaus K   Lind Judith J   Aksoy Osman O   Graichen Uwe U   Klee Sascha S   Herzog Franz F   Wiesner Christoph C   Errhalt Peter P   Pecherstorfer Martin M   Podar Klaus K   Vallet Sonia S  

Journal for immunotherapy of cancer 20240503 5


<h4>Background</h4>Skeletal morbidity in patients with cancer has a major impact on the quality of life, and preserving bone health while improving outcomes is an important goal of modern antitumor treatment strategies. Despite their widespread use in early disease stages, the effects of immune checkpoint inhibitors (ICIs) on the skeleton are still poorly defined. Here, we initiated a comprehensive investigation of the impact of ICIs on bone health by longitudinal assessment of bone turnover mar  ...[more]

Similar Datasets

2023-10-24 | PXD041819 | Pride
2020-04-29 | GSE134330 | GEO
2013-12-13 | E-GEOD-53155 | biostudies-arrayexpress
2021-09-09 | PXD019298 | Pride
2017-07-19 | E-MTAB-5847 | biostudies-arrayexpress
2018-11-04 | PXD010145 | Pride
2010-05-27 | E-GEOD-21523 | biostudies-arrayexpress
2024-05-29 | E-MTAB-13668 | biostudies-arrayexpress
2019-07-18 | PXD013158 | Pride
2020-01-09 | PXD008181 | Pride